[Research Advance of Venetoclax in Hematological Tumors--Review].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 28(4): 1419-1423, 2020 Aug.
Article
en Zh
| MEDLINE
| ID: mdl-32798437
Venetoclax is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2ï¼BCL-2ï¼and has great potential in treating a variety of hematological tumors. In recent years, domestic and foreign scholars have tried to use venetoclax singal or in combination with some drugs to treat the patients with hematological tumors, including elderly acute myeloid leukemiaï¼AMLï¼patients un suitable for intensive chemotherapy, relapsed or refractory chronic lymphocytic leukemiaï¼CLLï¼, Non-Hodgkin's lymphomaï¼NHLï¼and multiple myelomaï¼MMï¼patients, these studies have achieved good resultsï¼At the same timeï¼some scholars found that the secondary drug-resistance occurred in some patients who continuous treated with Venetoclax, and explored the Venetoclax-resistant mechanism. In this review, the research advance of Venetoclax in hematological tumors and the mechanisms of drug resistance are summarized and discussed briefly.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Leucemia Linfocítica Crónica de Células B
/
Neoplasias Hematológicas
/
Antineoplásicos
Límite:
Aged
/
Humans
Idioma:
Zh
Revista:
Zhongguo Shi Yan Xue Ye Xue Za Zhi
Asunto de la revista:
HEMATOLOGIA
Año:
2020
Tipo del documento:
Article
Pais de publicación:
China